Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers P > Headlines for Progenics Pharmaceuticals Inc. > News item |
Progenics reiterated by Merrill Lynch at buy
Progenics Inc. was reiterated by Merrill Lynch analyst David Munno at a buy rating with a price target on the stock of $28 per share following second-quarter results. Progenics shares Wednesday were down $0.04, or 0.18%, at $22.67 on volume of 124,880 shares versus the three-month running average of 168,774 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.